319 related articles for article (PubMed ID: 6810288)
1. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
2. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
Grosset J; Truffot-Pernot C; Poggi S; Lecoeur H; Chastang C
Rev Mal Respir; 1985; 2(4):205-8. PubMed ID: 3937188
[TBL] [Abstract][Full Text] [Related]
3. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
Lecoeur HF; Truffot-Pernot C; Grosset JH
Am Rev Respir Dis; 1989 Nov; 140(5):1189-93. PubMed ID: 2817579
[TBL] [Abstract][Full Text] [Related]
4. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Grosset J; Truffot-Pernot C; Lacroix C; Ji B
Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
[TBL] [Abstract][Full Text] [Related]
5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
6. The chemotherapy of tuberculous meningitis in children and adults.
Donald PR
Tuberculosis (Edinb); 2010 Nov; 90(6):375-92. PubMed ID: 20810322
[TBL] [Abstract][Full Text] [Related]
7. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
8. [Tuberculosis treatment today].
Nowak D; Radenbach D; Kirsten D; Magnussen H
Z Gesamte Inn Med; 1991 Aug; 46(10-11):404-9. PubMed ID: 1926948
[TBL] [Abstract][Full Text] [Related]
9. [Activity of rifampicin administered daily and intermittently on experimental tuberculosis in mice].
Grosset J; Truffot-Pernot C; Lecoeur H; Guelpa-Lauras CC
Pathol Biol (Paris); 1983 May; 31(5):446-50. PubMed ID: 6353339
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil.
Höfling CC; Pavan EM; Giampaglia CM; Ferrazoli L; Aily DC; de Albuquerque DM; Ramos MC
Int J Tuberc Lung Dis; 2005 Jan; 9(1):87-93. PubMed ID: 15675556
[TBL] [Abstract][Full Text] [Related]
11. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment.
Kam KM; Yip CW
Int J Tuberc Lung Dis; 2001 Sep; 5(9):815-23. PubMed ID: 11573892
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistant tuberculosis in Budapest.
Fodor T; Vadász I; Lõrinczi I
Int J Tuberc Lung Dis; 1998 Sep; 2(9):732-5. PubMed ID: 9755927
[TBL] [Abstract][Full Text] [Related]
15. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
[TBL] [Abstract][Full Text] [Related]
16. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice.
Lecoeur HF; Lagrange PH; Truffot-Pernot C; Gheorghiu M; Grosset J
Clin Exp Immunol; 1989 Jun; 76(3):458-62. PubMed ID: 2502336
[TBL] [Abstract][Full Text] [Related]
17. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
[TBL] [Abstract][Full Text] [Related]
18. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
[TBL] [Abstract][Full Text] [Related]
19. [Resistance of the Koch bacillus to antibacillary agents in the Department of the Lower Rhine].
Cooreman J; Burghard G; Grosset J
Rev Fr Mal Respir; 1983; 11(5):699-704. PubMed ID: 6419307
[TBL] [Abstract][Full Text] [Related]
20. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
Hu Y; Coates AR; Mitchison DA
Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
